Drug Trial Radar · NCT07870278
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Jul 5, 2031
Study completion Jul 7, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment. MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people. The goals of this trial are to learn about: * The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems. * What happens to different dose levels (amounts) of MK-6255 in the body over time.
Conditions
- Ovarian Neoplasms
- Endometrial Neoplasms
Interventions
MK-6255Biological
During initial dose escalation, participants will receive MK-6255 one weekly (QW). During Dose Interval Extension, participants will receive target doses every 3 weeks (Q3W).
CD8 PET TracerOther
Participants may receive an optional CD8 PET tracer for exploratory imaging assessments.
AcetaminophenDrug
Participants will receive acetaminophen (or similar antipyretic) as premedication.
DiphenhydramineDrug
Participants will receive diphenhydramine (or similar antihistamine) as premedication.
DexamethasoneDrug
Participants will receive dexamethasone as premedication.
TocilizumabBiological
Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.
Tocilizumab biosimilarBiological
Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.
SiltuximabBiological
Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0Time frame: Up to 21 days at each dose level
- Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 56 months
- Number of participants who discontinue study intervention due to an adverse event (AE)Time frame: Up to approximately 56 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
START New Jersey ( Site 0808)
East Brunswick, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.